http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 16:05:47 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html <p>Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.</p> <p>The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.</p> <p>The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html Mon, 24 Aug 2026 16:05:47 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html <p>Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.</p> <p>The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.</p> <p>The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html Mon, 24 Aug 2026 16:05:47 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html <p>Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.</p> <p>The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.</p> <p>The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html Mon, 24 Aug 2026 16:05:47 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html <p>Savara Inc. (Nasdaq: SVRA) announced that one oral presentation and two poster presentations on data from its Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution will be featured at the European Respiratory Society (ERS) Congress in Barcelona, Spain, from September 5–9, 2026.</p> <p>The presentations focus on molgramostim, an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no currently approved pharmacologic treatments.</p> <p>The oral presentation, scheduled for September 6, will cover long-term efficacy and safety results from the open-label period of the IMPALA-2 trial, including data through 48 weeks. It http://www.streetinsider.com/FDA/Savara+to+present+IMPALA-2+trial+data+at+ERS+Congress+in+Barcelona/26968088.html Mon, 24 Aug 2026 16:05:47 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Press+Releases/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html <p class="bwalignc"><i>-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --</i></p> <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54593814&amp;newsitemid=20260824428528&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=e054764ceb7b46ab75d5bb0b82dfabb9" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.</p><p>“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of aPAP lung disease severity suggest it may http://www.streetinsider.com/Business+Wire/Savara+Announces+Encore+Presentations+of+Results+from+the+Phase+3+Clinical+Trial+of+Molgramostim+Inhalation+Solution+%28Molgramostim%29+in+Autoimmune+Pulmonary+Alveolar+Proteinosis+%28APAP%29+at+the+European+/26968073.html Mon, 24 Aug 2026 16:05:00 -0400 A.20023828 O.01272850 O.38741611 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26956133.html <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com&amp;esheet=54592826&amp;newsitemid=20260820546931&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=c3b84c43c222ef69ed970af04cb5c941" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26956133.html Thu, 20 Aug 2026 16:05:00 -0400 O.01272850 SVRA http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26956133.html <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com&amp;esheet=54592826&amp;newsitemid=20260820546931&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=c3b84c43c222ef69ed970af04cb5c941" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan http://www.streetinsider.com/Press+Releases/Savara+Announces+New+Employment+Inducement+Grant/26956133.html Thu, 20 Aug 2026 16:05:00 -0400 O.01272850 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26956133.html <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com&amp;esheet=54592826&amp;newsitemid=20260820546931&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=c3b84c43c222ef69ed970af04cb5c941" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26956133.html Thu, 20 Aug 2026 16:05:00 -0400 O.01272850 SVRA http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26956133.html <p> YARDLEY, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com&amp;esheet=54592826&amp;newsitemid=20260820546931&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=c3b84c43c222ef69ed970af04cb5c941" shape="rect">Savara Inc.</a> (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. </p><p> On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company’s common stock and restricted stock units (RSUs) covering 64,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan http://www.streetinsider.com/Business+Wire/Savara+Announces+New+Employment+Inducement+Grant/26956133.html Thu, 20 Aug 2026 16:05:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Savara+Inc.++++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925035.html si-local-file:///var/storage/secattach/20260814/26925035.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Savara+Inc.++++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925035.html Fri, 14 Aug 2026 08:23:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Savara+Inc.++++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925035.html si-local-file:///var/storage/secattach/20260814/26925035.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Savara+Inc.++++++++++++++++++++++++++++Filed+by%3A+FARALLON+CAPITAL+MANAGEMENT%2C+L.L.C./26925035.html Fri, 14 Aug 2026 08:23:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Savara+Inc+++++++++++++++++++++++++++/26907000.html si-local-file:///var/storage/secattach/20260811/26907000.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Savara+Inc+++++++++++++++++++++++++++/26907000.html Tue, 11 Aug 2026 17:12:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Savara+Inc+++++++++++++++++++++++++++/26907000.html si-local-file:///var/storage/secattach/20260811/26907000.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Savara+Inc+++++++++++++++++++++++++++/26907000.html Tue, 11 Aug 2026 17:12:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Savara+Inc++++++++++++++++For%3A+Jun+30/26905632.html si-local-file:///var/storage/secattach/20260811/26905632.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Savara+Inc++++++++++++++++For%3A+Jun+30/26905632.html Tue, 11 Aug 2026 16:06:00 -0400 O.01272850 SVRA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Savara+Inc++++++++++++++++For%3A+Jun+30/26905632.html si-local-file:///var/storage/secattach/20260811/26905632.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Savara+Inc++++++++++++++++For%3A+Jun+30/26905632.html Tue, 11 Aug 2026 16:06:00 -0400 O.01272850 SVRA http://www.streetinsider.com/Press+Releases/Savara+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905535.html <ul class="bwlistdisc"> <li> <i>MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026</i> </li> <li> <i>MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively</i> </li> <li> <i>Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life</i> </li> <li> <i>European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041</i> </li> <li> <i>~$173M in Cash and Short-Term Investments as of June 30, 2026, Plus up to ~$150M of Non-Dilutive Capital Upon FDA Approval of MOLBREEVI, Positions the Company Well for Launch</i> </li> </ul> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54587357&amp;newsitemid=20260811733978&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=78f5c33b35de68a81666d20a7eff47da" http://www.streetinsider.com/Press+Releases/Savara+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905535.html Tue, 11 Aug 2026 16:05:00 -0400 A.06822034 O.01272850 O.20026344 SVRA http://www.streetinsider.com/Press+Releases/Savara+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905535.html <ul class="bwlistdisc"> <li> <i>MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026</i> </li> <li> <i>MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively</i> </li> <li> <i>Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life</i> </li> <li> <i>European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041</i> </li> <li> <i>~$173M in Cash and Short-Term Investments as of June 30, 2026, Plus up to ~$150M of Non-Dilutive Capital Upon FDA Approval of MOLBREEVI, Positions the Company Well for Launch</i> </li> </ul> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54587357&amp;newsitemid=20260811733978&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=78f5c33b35de68a81666d20a7eff47da" http://www.streetinsider.com/Press+Releases/Savara+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905535.html Tue, 11 Aug 2026 16:05:00 -0400 A.06822034 O.01272850 O.20026344 SVRA http://www.streetinsider.com/Press+Releases/Savara+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905535.html <ul class="bwlistdisc"> <li> <i>MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026</i> </li> <li> <i>MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively</i> </li> <li> <i>Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life</i> </li> <li> <i>European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041</i> </li> <li> <i>~$173M in Cash and Short-Term Investments as of June 30, 2026, Plus up to ~$150M of Non-Dilutive Capital Upon FDA Approval of MOLBREEVI, Positions the Company Well for Launch</i> </li> </ul> <p> LANGHORNE, Pa.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsavarapharma.com%2F&amp;esheet=54587357&amp;newsitemid=20260811733978&amp;lan=en-US&amp;anchor=Savara+Inc.&amp;index=1&amp;md5=78f5c33b35de68a81666d20a7eff47da" http://www.streetinsider.com/Press+Releases/Savara+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905535.html Tue, 11 Aug 2026 16:05:00 -0400 A.06822034 O.01272850 O.20026344 SVRA